Home » Stocks » DBV Technologies

DBV Technologies S.A. (DBVT)

Stock Price: $2.40 USD -1.71 (-41.59%)
Updated Aug 4, 2020 11:35 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 262.93M
Revenue (ttm) n/a
Net Income (ttm) -172.57M
Shares Out 109.75M
EPS (ttm) -3.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $2.40
Previous Close $4.10
Change ($) -1.71
Change (%) -41.59%
Day's Open 2.58
Day's Range 2.32 - 2.60
Day's Volume 3,895,120
52-Week Range 2.02 - 13.49

More Stats

Market Cap 262.93M
Enterprise Value 96.78M
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 109.75M
Float 35.99M
EPS (basic) n/a
EPS (diluted) -3.27
FCF / Share -4.97
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.79M
Short Ratio 9.02
Short % of Float n/a
Beta 2.01
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.10
Revenue n/a
Operating Income -185.21M
Net Income -172.57M
Free Cash Flow -150.02M
Net Cash 166.14M
Net Cash / Share 1.52
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -35.72%
ROE -94.15%
ROIC -568.10%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (11)

Buy 6
Overweight 0
Hold 4
Underweight 1
Sell 0

Analyst Consensus: Overweight

Price Target

(350.04% upside)
Current: $2.40
Target: 10.78
*Average 12-month USD price target from 11 stock analysts.

Financial Performance

Financial numbers in millions EUR.

Financial Overview

Revenue Growth-----4.27%15.93%4.38%-
Gross Profit----
Operating Income-165-181-157-125-51.51-29.19-23.60-16.01
Net Income-154-166-148-115-44.67-24.01-19.31-12.91
Shares Outstanding30.1624.9924.6524.2119.1619.16--
Earnings Per Share-4.15-5.74-5.97-4.68-2.08-1.49-1.42-1.05
Operating Cash Flow-129-137-114-59.54-26.76-20.56-13.25-10.43
Capital Expenditures-5.00-4.75-7.55-8.21-4.51-0.97-1.17-0.36
Free Cash Flow-134-141-122-67.75-31.27-21.53-14.42-10.79
Cash & Equivalents17212313825632311539.4038.35
Total Debt24.162.484.154.644.844.131.441.15
Net Cash / Debt14812013425231911037.9637.19
Book Value17212113024332211540.4039.17
Numbers in millions EUR, except per-share numbers.

Company Profile

Company Details

Full Name DBV Technologies S.A.
Country France
Employees 311
CEO Daniel Tassé

Stock Information

Ticker Symbol DBVT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: DBVT


DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.